Jonathan Lowman, MD
Internal Medicine · Union City, GANPI 1699748061
Payments from drug & device makers
Across 286 payments — averaging $33.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$5K
- Novo Nordisk$740
- Pfizer$668
- Lilly USA, LLC$567
- AbbVie$545
- AstraZeneca$451
- plus $2K from 25 others
What the payments were for
- Consulting fees$4,58348%
- Food & beverage$4,87551%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 5 | $4,583 |
| Novo Nordisk | 41 | $740 |
| Pfizer | 36 | $668 |
| Lilly USA, LLC | 41 | $567 |
| AbbVie | 37 | $545 |
| AstraZeneca | 25 | $451 |
| Novartis | 11 | $221 |
| Johnson & Johnson | 10 | $211 |
| Boehringer Ingelheim | 9 | $196 |
| GSK | 11 | $190 |
| Sanofi-aventis U.S. LLC | 8 | $148 |
| Astellas Pharma US Inc | 7 | $135 |
| Amgen | 8 | $128 |
| Exact Sciences | 7 | $95 |
| Idorsia Pharmaceuticals US Inc | 4 | $81 |
| Dexcom, Inc. | 4 | $78 |
| Abbott | 3 | $63 |
| Shield Therapeutics Inc | 2 | $44 |
| Bayer | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Merck | 2 | $34 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PAXLOVID$109
How this compares
$9,471 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $210,179 |
| EliquisApixaban | 109 | $123,681 |
| FarxigaDapagliflozin Propanediol | 104 | $109,821 |
| JanuviaSitagliptin Phosphate | 92 | $99,173 |
| JardianceEmpagliflozin | 79 | $98,059 |
| TrulicityDulaglutide | 34 | $63,655 |
| MounjaroTirzepatide | 45 | $63,475 |
| TivicayDolutegravir Sodium | 12 | $30,520 |
| MyrbetriqMirabegron | 19 | $21,014 |
| XareltoRivaroxaban | 65 | $20,208 |
| EvotazAtazanavir Sulfate/Cobicistat | 11 | $19,876 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $19,693 |
| EntrestoSacubitril/Valsartan | 14 | $17,748 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $13,871 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $11,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $740 | $210,179147 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $567 | $129,59391 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $451 | $128,213140 claims |
| PfizerEliquis | $668 | $123,681109 claims |
| Boehringer IngelheimJardiance, Tradjenta | $196 | $109,03690 claims |
| MerckJanuvia, Janumet Xr | $34 | $107,490103 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $190 | $27,97631 claims |
| Astellas Pharma US IncMyrbetriq | $135 | $21,01419 claims |
| Johnson & JohnsonXarelto | $211 | $20,20865 claims |
| NovartisEntresto | $221 | $17,74814 claims |
| AbbVieSynthroid | $545 | $2,30929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Union City
- Dwight BlakeUnion City$13.3M
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.